It is interesting to study the efficacy of anti-KIR monoclonal antibodies in maintenance therapy in acute myeloid leukemia (EFFIKIR) where the drug was administered to groups at different doses 0.1 mg/kg and 1 mg/kg (NCT01687387). The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.